Yayınlar & Eserler

Yayın Ağı

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.
BMC CANCER , sa.1, 2024 (SCI-Expanded) identifier identifier

Real-Life Experience with Entrectinib in Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Solid Tumors: A Multicenter Retrospective Trial

YILMAZ F., YAŞAR S., Mandel N. M., Kacan T., Ozdemir M., DOĞU G. G., et al.
TARGETED ONCOLOGY , 2024 (SCI-Expanded) identifier identifier

Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

KUTLU Y., Dae S. A., YILMAZ F., Erdem D., Sendur M. A. N., Akbas S., et al.
CANCERS , sa.12, 2024 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights From a Multi-Center Study

Yaşar S., Yilmaz F., Utkan G., Algın E., Bayram D., Tamam S., et al.
ANNALS OF SURGICAL ONCOLOGY , cilt.31, sa.6, ss.1-9, 2024 (SCI-Expanded) identifier

Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort

AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.
Medicine (United States) , cilt.102, sa.18, 2023 (SCI-Expanded) identifier identifier

The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma

GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., et al.
European Archives of Oto-Rhino-Laryngology , cilt.280, sa.5, ss.2471-2478, 2023 (SCI-Expanded) identifier identifier identifier

Emerging treatment strategies in hepatobiliary cancer

GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.
Expert Review of Anticancer Therapy , cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.17, 2022 (SCI-Expanded) Creative Commons License identifier identifier identifier

Complete response in a frail patient with high-grade B-cell lymphoma to only one cycle of R-CHOP or to prolonged COVID-19?

Yilmaz F., Yasar S., Tuncali M. C., Akin S.
Seminars in oncology , cilt.48, sa.4-6, ss.279-282, 2021 (SCI-Expanded) identifier

Diğer Dergilerde Yayınlanan Makaleler

Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.
Journal of Oncological Science , cilt.9, sa.1, ss.33-37, 2023 (Scopus) Creative Commons License identifier identifier

Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.6, sa.1, ss.59-63, 2022 (ESCI) Sürdürülebilir Kalkınma identifier identifier identifier

Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.
Journal of Oncological Science , cilt.8, sa.3, ss.143-147, 2022 (Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

Metrikler

Yayın

12

Atıf (Scopus)

4

H-İndeks (Scopus)

2

Açık Erişim

4
BM Sürdürülebilir Kalkınma Amaçları